BRCA2 and cancer: To evaluate the molecular profile of C220, we evaluated changes in global gene expression by RNA-seq following C220 treatment in HR-proficient breast (MCF7) and ovarian (A2780), and HR-deficient breast (HCC1569; BRCA2 mut) cancer cell lines.